ITGA2B and non-small cell lung carcinoma: (50) described that ITGA2B levels in TEPs were significantly higher in non-small cell lung cancer (NSCLC) patients than in controls, which could be a promising marker to improve the identification of stage I NSCLC patients and distinguish the benign and malignant pulmonary nodules.